Merck: more evidence on ertugliflozin in type-2 diabetes.
(CercleFinance.com) - Merck in partnership with Pfizer said that two Phase 3 studies on ertugliflozin, their investigational oral inhibitor that is being developed to help improve glycemic control in adults with type-2 diabetes, met their primary endpoints.
In the studies, both doses of ertugliflozin tested achieved statistically significant reductions in A1C, a measure of average blood glucose over a two-to-three month timeframe, when added to metformin, or in initial co-administration with sitagliptin.
The results - presented at the scientific sessions of the American Diabetes Association (ADA) in San Diego - support ertugliflozin's product profile as an add-on therapy to metformin or for first-line use when combined with sitagliptin, the companies said.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In the studies, both doses of ertugliflozin tested achieved statistically significant reductions in A1C, a measure of average blood glucose over a two-to-three month timeframe, when added to metformin, or in initial co-administration with sitagliptin.
The results - presented at the scientific sessions of the American Diabetes Association (ADA) in San Diego - support ertugliflozin's product profile as an add-on therapy to metformin or for first-line use when combined with sitagliptin, the companies said.
Copyright (c) 2017 CercleFinance.com. All rights reserved.